Results 11 to 20 of about 208,828 (307)

Macrocyclic Histone Deacetylase Inhibitors [PDF]

Current Topics in Medicinal Chemistry, 2010
Histone deacetylase inhibitors (HDACi) are an emerging class of novel anti-cancer drugs that cause growth arrest, differentiation, and apoptosis of tumor cells. In addition, they have shown promise as anti-parasitic, anti-neurodegenerative, anti-rheumatologic and immunosuppressant agents. To date, several structurally distinct small molecule HDACi have
Sandra C, Mwakwari, Vishal, Patil, William, Guerrant, Adegboyega K, Oyelere   +3 more
openaire   +2 more sources

Histone deacetylase inhibitors and transplantation [PDF]

Current Opinion in Immunology, 2007
Simply detecting the presence or absence of Foxp3, a transcription factor characteristic of naturally occurring CD4+ CD25+ regulatory T cells (Tregs), now appears of minimal value in predicting the outcome of immunologic responses, since dividing human CD4+ effector T cells can induce Foxp3 without attaining repressive functions, and additional ...
Ran, Tao, Edwin F, de Zoeten, Engin, Ozkaynak, Liqing, Wang, Bin, Li, Mark I, Greene, Andrew D, Wells, Wayne W, Hancock   +7 more
openaire   +2 more sources

Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy

Frontiers in Oncology, 2020
Evidence for research over the past decade shows that epigenetic regulation mechanisms run through the development and prognosis of tumors. Therefore, small molecular compounds targeting epigenetic regulation have become a research hotspot in the ...
Donglu Wu, Donglu Wu, Ye Qiu, Ye Qiu, Yunshuang Jiao, Zhidong Qiu, Zhidong Qiu, Da Liu, Da Liu   +8 more
doaj   +1 more source

Design, synthesis, and biological evaluation of novel histone deacetylase 6 selective inhibitors

Journal of Saudi Chemical Society, 2022
Histone deacetylase 6 (HDAC6) is distinguished from other HDACs by its ability to deacetylate α-tubulin and HSP90, and was reported to be related to a variety of human diseases, such as cancers, neurodegenerative diseases, and immunological disorders ...
Tianyi Zhang, Xiaoyan Zhao, Xiangpei Sun, Wei Tian, Chongqing Wang, Mingping Wang, Yi Zhang, Xin Chen, Canhui Zheng   +8 more
doaj   +1 more source

Pharmacogenomics and Histone Deacetylase Inhibitors [PDF]

Pharmacogenomics, 2016
The histone deacetylase inhibitor valproic acid (VPA) has been used for many decades in neurology and psychiatry. The more recent introduction of the histone deacetylase inhibitors (HDIs) belinostat, romidepsin and vorinostat for treatment of hematological malignancies indicates the increasing popularity of these agents.
Andrew Kl, Goey, Tristan M, Sissung, Cody J, Peer, William D, Figg   +3 more
openaire   +2 more sources

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report

Haematologica, 2009
Histone deacetylase inhibitors are a class of anti-neoplastic agents that induce growth arrest, differentiation, and/or apoptotic cell death of transformed cells in vitro and in vivo.
David Ritchie, Richard L. Piekarz, Piers Blombery, Laszlo J. Karai, Stefania Pittaluga, Elaine S. Jaffe, Mark Raffeld, John E. Janik, H. Miles Prince, Susan E. Bates   +9 more
doaj   +1 more source

Inhibition of histone deacetylase as a treatment for cardiac hypertrophy [PDF]

, 2005
The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac ...
Bristow, Michael R., Long, Carlin, McKinsey, Timothy A., Olson, Eric N.   +3 more
core   +1 more source

Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor

Science, 2012
Stress Protector During prolonged fasting, the oxidation of fatty acids leads to increased accumulation of d-β-hydroxybutyrate (βOHB) in the bloodstream. Such increased concentrations of βOHB inhibit class I histone deacetylases.
Tadahiro Shimazu, M. Hirschey, John Newman, Wenjuan He, Kotaro Shirakawa, Natacha Le Moan, Carrie A. Grueter, Hyungwook Lim, Laura R. Saunders, Robert D. Stevens, Christopher B. Newgard, R. Farese, R. de Cabo, Scott M. Ulrich, Katerina Akassoglou, E. Verdin   +15 more
semanticscholar   +1 more source

Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas

Haematologica, 2018
Histone deacetylase inhibitors are promising agents for various T-cell lymphomas, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and adult T-cell lymphoma/leukemia. CCR4 is an important therapeutic target molecule because mogamulizumab,
Akihiro Kitadate, Sho Ikeda, Fumito Abe, Naoto Takahashi, Norio Shimizu, Kosei Matsue, Hiroyuki Tagawa   +6 more
doaj   +1 more source

Comprehensive suppression of all apoptosis-induced proliferation pathways as a proposed approach to colorectal cancer prevention and therapy. [PDF]

PLoS ONE, 2014
Mutations in the WNT/beta-catenin pathway are present in the majority of all sporadic colorectal cancers (CRCs), and histone deacetylase inhibitors induce apoptosis in CRC cells with such mutations.
Michael Bordonaro, Eric Drago, Wafa Atamna, Darina L Lazarova   +3 more
doaj   +1 more source